Kantar Health Oncology Experts and Synix Inc. to Host 9th Annual Seminar in Tokyo
NEW YORK, June 27, 2013—Kantar Health, a leading global healthcare consulting firm, today announced that it will host its ninth annual seminar highlighting the implications of recent drug approvals and clinical results in the oncology competitive landscape. The seminar is presented in conjunction with Synix Inc., Kantar Health’s partner in Japan.
The seminar, “Oncology Conference Insight: Implications from Recent Clinical Developments,” will take place at Conference Square M+ in Tokyo on Thursday, July 4, from 1 to 5 pm and will be led by Kantar Health oncology specialists Stephanie Hawthorne, Ph.D., Director, Clinical & Scientific Assessment; Neesha Suvarna, Ph.D., Consultant, Clinical & Scientific Assessment; and Gordon Gochenauer, Director, Oncology Commercial Strategies. The seminar will discuss the impact of new drug approvals and recent clinical data on treatment paradigms, pricing and market access issues for these agents and indications, and the implications for future drug development in several tumor types:
Advances in immunotherapy will also be discussed, focusing on development strategies for PD-1/PD-L1 inhibitors, vaccines and other immunotherapeutics.
To register for “Oncology Conference Insight: Implications from Recent Clinical Developments,” please visit www.synix.co.jp or contact Yoko Nagahisa, Synix Oncology Market Assessment, at email@example.com.
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.